As a result of the Merger, and the automatic conversion of NeoStem's Series D Convertible Preferred Stock into an aggregate of 12,932,510 shares of NeoStem Common Stock, which was also approved at the Special Meeting, the ownership of the NeoStem Common Stock outstanding is approximately as follows:

Number of Shares*

Percentage Ownership

Beneficial Ownership*

RimAsia Capital Partners, L.P.
11,458,009 31.4% 50.5%
Erye Economy & Trading Co. (including Madam Zhang n Mr. Shi)
4,234,918 11.6% 14.1%
Enhance Biomedical Holding Corporation
4,000,000 11.0% 19.8%
HHolders of Series D Convertible Redeemable Preferred Stock as converted into common stock (excluding RimAsia, EET/Fullbright and Enhance Biomedical)
4,292,510 11.8% 21.1%
Historic NeoStem Shareholders (other than those listed above)
7,947,749 21.8% -
Former CBH Shareholders (other than those listed above)
4,520,735 12.4% -

*The shares reflected in the number of shares column above (i) does not include (a) 9,086,124 shares of common stock which may be acquired by RimAsia by virtue of conversion of the Company's Series C Convertible Preferred Stock or (b) shares which may be acquired upon exercise of outstanding NeoStem stock options and warrants (5,000,000 held by RimAsia, 1,040,000 held by EET/Fullbright and 4,000,000 held by Enhance), and (ii) does include an aggregate of 553,338 shares of common stock to be issued to Fullbright, Mr. Shi and Madam Zhang upon the receipt of PRC approvals as described in this Note 10. The beneficial ownership column reflects any of such shares which might be issued in the next 60 days in computing beneficial ownership in accordance with SEC rules.

So, it looks as though we have about 40 mil shares BEFORE the warrants are exercised. RIMASIA will convert in time.

As of today, over the next 12 months, we should have 80 Mil$ in revs on 40 mil shares.

Next report on Jan 1 should be very interesting.